$PMDI
PSYCHEMEDICS CORP Stock $pmdi

$pmdi Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000117184323007042 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$4.998M	$5.704M	$5.703M
YoY Change	-12.36%	-12.46%	-11.39%
Cost Of Revenue	$2.940M	$3.613M	$3.458M
YoY Change	-14.98%	-13.65%	-18.65%
Gross Profit	$2.058M	$2.091M	$2.245M
YoY Change	-8.33%	-10.33%	2.75%
Gross Profit Margin	41.18%	36.66%	39.37%
Selling, General & Admin	$2.641M	$2.923M	$2.278M
YoY Change	15.94%	22.87%	-19.7%
% of Gross Profit	128.33%	139.79%	101.47%
Research & Development	$285.0K	$275.0K	$323.0K
YoY Change	-11.76%	-16.16%	3.19%
% of Gross Profit	13.85%	13.15%	14.39%
Depreciation & Amortization	$341.0K	$450.0K	$531.0K
YoY Change	-35.78%	-24.62%	-18.31%
% of Gross Profit	16.57%	21.52%	23.65%
Operating Expenses	$2.926M	$3.198M	$2.601M
YoY Change	12.5%	18.14%	-17.43%
Operating Profit	-$868.0K	-$1.107M	-$356.0K
YoY Change	143.82%	195.2%	-63.11%
Interest Expense	-$3.000K	$0.00	-$6.000K
YoY Change	-50.0%	-100.0%	-64.71%
% of Operating Profit
Other Income/Expense, Net	$2.000K	$0.00
YoY Change		-100.0%
Pretax Income	-$876.0K	-$1.107M	-$362.0K
YoY Change	141.99%	189.03%	-82.4%
Income Tax	$69.00K	$992.0K	$326.0K
% Of Pretax Income
Net Earnings	-$945.0K	-$2.099M	-$688.0K
YoY Change	37.35%	2063.92%	-57.56%
Net Earnings / Revenue	-18.91%	-36.8%	-12.06%
Basic Earnings Per Share		-$0.36
Diluted Earnings Per Share	-$0.16	-$0.36	-$0.12
COMMON SHARES
Basic Shares Outstanding	5.802M	5.743M	5.645M
Diluted Shares Outstanding		5.755M

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.964M	$1.370M	$4.750M
YoY Change	-58.65%	-60.38%	138.45%
Cash & Equivalents	$1.964M	$1.370M	$4.750M
Short-Term Investments
Other Short-Term Assets	$1.136M	$1.520M	$1.136M
YoY Change	0.0%	0.66%	-24.22%
Inventory
Prepaid Expenses
Receivables	$3.687M	$4.596M	$3.739M
Other Receivables	$18.00K	$380.0K	$339.0K
Total Short-Term Assets	$6.805M	$7.872M	$9.964M
YoY Change	-31.7%	-26.59%	-3.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.889M	$5.420M	$7.254M
YoY Change	-32.6%	-32.05%	8.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$632.0K	$809.0K	$1.514M
YoY Change	-58.26%	-4.03%	75.23%
Total Long-Term Assets	$5.521M	$6.232M	$8.768M
YoY Change	-37.03%	-36.11%	-22.18%
TOTAL ASSETS
Total Short-Term Assets	$6.805M	$7.872M	$9.964M
Total Long-Term Assets	$5.521M	$6.232M	$8.768M
Total Assets	$12.33M	$14.10M	$18.73M
YoY Change	-34.2%	-31.13%	-13.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$752.0K	$817.0K	$448.0K
YoY Change	67.86%	-4.67%	-54.93%
Accrued Expenses	$3.652M	$3.208M	$4.976M
YoY Change	-26.61%	-19.28%	56.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$305.0K	$302.0K	$294.0K
YoY Change	3.74%	-16.11%	-55.72%
Total Short-Term Liabilities	$4.709M	$5.385M	$5.718M
YoY Change	-17.65%	-12.81%	-1.92%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$77.00K	$305.0K
YoY Change	-100.0%	-79.74%	-49.08%
Other Long-Term Liabilities	$945.0K	$1.210M	$1.938M
YoY Change	-51.24%	-45.0%	-32.71%
Total Long-Term Liabilities	$945.0K	$77.00K	$2.243M
YoY Change	-57.87%	-79.74%	274.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.709M	$5.385M	$5.718M
Total Long-Term Liabilities	$945.0K	$77.00K	$2.243M
Total Liabilities	$5.654M	$6.675M	$7.961M
YoY Change	-28.98%	-23.77%	-14.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$16.77M	-$15.83M	-$11.82M
YoY Change	41.9%	47.47%	23.77%
Common Stock	$35.16M	$34.97M	$34.31M
YoY Change	2.49%	2.35%	2.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$10.08M		$10.08M
YoY Change	0.0%		0.0%
Treasury Stock Shares			$668.0K
Shareholders Equity	$6.672M	$7.429M	$10.77M
YoY Change
Total Liabilities & Shareholders Equity	$12.33M	$14.10M	$18.73M
YoY Change	-34.2%	-31.13%	-13.08%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$945.0K	-$2.099M	-$688.0K
YoY Change	37.35%	2063.92%	-57.56%
Depreciation, Depletion And Amortization	$341.0K	$450.0K	$531.0K
YoY Change	-35.78%	-24.62%	-18.31%
Cash From Operating Activities	$660.0K	-$960.0K	$1.894M
YoY Change	-65.15%	-141.13%	235.22%
INVESTING ACTIVITIES
Capital Expenditures	$27.00K	$30.00K	$24.00K
YoY Change	12.5%	-132.97%	-180.0%
Acquisitions
YoY Change
Other Investing Activities	$28.00K	-$10.00K	$4.000K
YoY Change	600.0%	42.86%	0.0%
Cash From Investing Activities	$1.000K	-$40.00K	-$20.00K
YoY Change	-105.0%	-59.18%	-23.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-77.00K	-70.00K	-582.0K
YoY Change	-86.77%	-87.68%	13.01%
NET CHANGE
Cash From Operating Activities	660.0K	-960.0K	1.894M
Cash From Investing Activities	1.000K	-40.00K	-20.00K
Cash From Financing Activities	-77.00K	-70.00K	-582.0K
Net Change In Cash	584.0K	-1.070M	1.292M
YoY Change	-54.8%	-164.15%	5283.33%
FREE CASH FLOW
Cash From Operating Activities	$660.0K	-$960.0K	$1.894M
Capital Expenditures	$27.00K	$30.00K	$24.00K
Free Cash Flow	$633.0K	-$990.0K	$1.870M
YoY Change	-66.15%	-140.82%	214.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	PSYCHEMEDICS CORP
	dei	Entity Central Index Key EntityCentralIndexKey	0000806517
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	38000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	87000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23312000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21964000	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.005
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.005
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	873
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	873
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6470000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6349000
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5802000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5681000
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	668000
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	668000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2099000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-97000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3209000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-396000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9127000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	-0	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	401000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2099000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7429000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10771000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	1000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	54000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	721000	usd
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.07
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	799000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3209000	usd
CY2022Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	394000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-97000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	36000	usd
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.07
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	787000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-396000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3209000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-396000	usd
	us-gaap	Interest Paid Net InterestPaidNet	14000	usd
	us-gaap	Interest Paid Net InterestPaidNet	36000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	874000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	849000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	86000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	78000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	66000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	14.7
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	11000
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	1-13738
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-1701987
	dei	Entity Address Address Line1 EntityAddressAddressLine1	289 Great Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Acton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01720
	dei	City Area Code CityAreaCode	978
	dei	Local Phone Number LocalPhoneNumber	206-8220
	dei	Security12b Title Security12bTitle	Common stock. $0.005 par value
	dei	Trading Symbol TradingSymbol	PMD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5801761
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1370000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4750000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4596000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3739000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1524000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1136000	usd
CY2023Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	382000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	339000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	7872000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9964000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3357000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4573000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	809000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	823000	usd
CY2023Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	691000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2066000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2681000	usd
CY2023Q3	us-gaap	Assets Assets	14104000	usd
CY2022Q4	us-gaap	Assets Assets	18732000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	817000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	448000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3208000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3939000	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	302000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	294000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1058000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1037000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5385000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5718000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	77000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-727000	usd
CY2023Q3	pmd	Other Nonoperating Expense Settlement OtherNonoperatingExpenseSettlement	-0	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	305000	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1206000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1938000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	6675000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7961000	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	32000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	32000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	34941000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	34275000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15828000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11820000	usd
CY2023Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	10082000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	10082000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1634000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1634000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7429000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10771000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14104000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18732000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5704000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6516000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17100000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19537000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3613000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4184000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10745000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12492000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	2091000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	2332000	usd
	us-gaap	Gross Profit GrossProfit	6355000	usd
	us-gaap	Gross Profit GrossProfit	7045000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2200000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1588000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5291000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4360000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	723000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	791000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2258000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2409000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	275000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	328000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	859000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1003000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	3198000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2707000	usd
	us-gaap	Operating Expenses OperatingExpenses	8408000	usd
	us-gaap	Operating Expenses OperatingExpenses	7772000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1107000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-375000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2053000	usd
	pmd	Other Nonoperating Expense Settlement OtherNonoperatingExpenseSettlement	500000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	49000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-509000	usd
	pmd	Payments For Proceeds From Other Assets PaymentsForProceedsFromOtherAssets	32000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	49000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1107000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-383000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2562000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-678000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	992000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-286000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	647000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-282000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q3	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2022Q3	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.07
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.14
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.14
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7429000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11936000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	-0	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	277000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	11722000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12243000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	-0	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	694000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	11722000	usd
	pmd	Depreciation And Amortization Excluding Rou Asset Amortization DepreciationAndAmortizationExcludingRouAssetAmortization	1394000	usd
	pmd	Depreciation And Amortization Excluding Rou Asset Amortization DepreciationAndAmortizationExcludingRouAssetAmortization	1836000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	701000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	718000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	698000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-775000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	721000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	694000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	857000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	837000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	388000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	11000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	43000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-1875000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	369000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-137000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-797000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-757000	usd
	pmd	Increase Decrease In Accrued Expenses And Accrued Income Taxes IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes	-731000	usd
	pmd	Increase Decrease In Accrued Expenses And Accrued Income Taxes IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes	786000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2142000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2996000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24000	usd
	pmd	Payments For Proceeds From Other Assets PaymentsForProceedsFromOtherAssets	25000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	60000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	108000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	103000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-164000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-188000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-55000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-32000	usd
	pmd	Payments Of Equipment Financing PaymentsOfEquipmentFinancing	220000	usd
	pmd	Payments Of Equipment Financing PaymentsOfEquipmentFinancing	523000	usd
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	799000	usd
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	787000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1074000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1342000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3380000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1466000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4750000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1992000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1370000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3458000	usd
CY2023Q3	us-gaap	Cash Cash	1400000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	505000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	401000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	277000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	721000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	694000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	508000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.19
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	120000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.66
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.07
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	551000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.87
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M24D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	431000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.4
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y2M12D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	692000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5755000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5638000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5718000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5613000
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5755000
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5638000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5718000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5613000
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	524000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	513000
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2100000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2300000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.039	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	258000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	779000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	293000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1106000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	564000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	460000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2423000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	159000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2264000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1058000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1206000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2264000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5704000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6516000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17100000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19537000	usd

Files In Submission

Name	View Source	Status
0001171843-23-007042-index-headers.html	Edgar Link	pending
0001171843-23-007042-index.html	Edgar Link	pending
0001171843-23-007042.txt	Edgar Link	pending
0001171843-23-007042-xbrl.zip	Edgar Link	pending
ex_590982.htm	Edgar Link	pending
ex_590984.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pmd-20230930.xsd	Edgar Link	pending
pmd20230930_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
pmd-20230930_cal.xml	Edgar Link	unprocessable
pmd-20230930_def.xml	Edgar Link	unprocessable
pmd-20230930_pre.xml	Edgar Link	unprocessable
pmd20230930_10q_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pmd-20230930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PMDI
PSYCHEMEDICS CORP Stock $pmdi

2023 Q4 Form 10-Q Financial Statement

#000117184323007042 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMDI PSYCHEMEDICS CORP Stock $pmdi

2023 Q4 Form 10-Q Financial Statement

#000117184323007042 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMDI
PSYCHEMEDICS CORP Stock $pmdi